Impact of higher hemoglobin targets on blood pressure and clinical outcomes: A secondary analysis of CHOIR

Nephrology Dialysis Transplantation

Volumn 27, Issue 9, 2012, Pages 3606-3614

  Inrig, Jula K ^a,b   Sapp, Shelly ^c   Barnhart, Huiman ^d   Patel, Uptal D ^a,c   Reddan, Donal ^a,e   Singh, Ajay ^f   Califf, Robert M ^d   Szczech, Lynda ^a,c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

anemia; blood pressure; cardiovascular events; chronic kidney disease; erythropoietin dose

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GUANFACINE; HEMOGLOBIN; HYDRALAZINE; MINOXIDIL; RECOMBINANT ERYTHROPOIETIN;

ADVERSE OUTCOME; AGED; ANEMIA; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD PRESSURE VARIABILITY; CARDIOVASCULAR RESPONSE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEATH; DEMOGRAPHY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY ANALYSIS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

AGED; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84865734270     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs123     Document Type: Article

References (34)

1. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032.
2. Phrommintikul A, Haas SJ, Elsik M et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007; 369: 381-388.
3. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098.
4. Fishbane S, Besarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol 2007; 2: 1274-1282.
5. Yang W, Israni RK, Brunelli SM et al. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 2007; 18: 3164-3170.
6. Abraham PA, Macres MG. Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. J Am Soc Nephrol 1991; 2: 927-936.
7. Krapf R, Hulter HN. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA). Clin J Am Soc Nephrol 2009; 4: 470-480.
8. Lebel M, Kingma I, Grose JH et al. Hemodynamic and hormonal changes during erythropoietin therapy in hemodialysis patients. J Am Soc Nephrol 1998; 9: 97-104.
9. Raine AE, Roger SD. Effects of erythropoietin on blood pressure. Am J Kidney Dis 1991; 18: 76-83.
10. Cody J, Daly C, Campbell M et al. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev 2005; (3): CD003266.
11. Palmer SC, Navaneethan SD, Craig JC et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 2010; 153: 23-33.
12. Strippoli GF, Craig JC, Manno C et al. Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials. J Am Soc Nephrol 2004; 15: 3154-3165.
13. Kaupke CJ, Kim S, Vaziri ND. Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy. J Am Soc Nephrol 1994; 4: 1874-1878.
14. Heidenreich S, Rahn KH, Zidek W. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int 1991; 39: 259-265.
15. Vaziri ND, Zhou XJ, Smith J et al. In vivo and in vitro pressor effects of erythropoietin in rats. Am J Physiol 1995; 269: F838-F845.
16. Carlini R, Obialo CI, Rothstein M. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients. Am J Hypertens 1993; 6: 103-107.
17. Carlini RG, Dusso AS, Obialo CI et al. Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int 1993; 43: 1010-1014.
18. Scalera F, Kielstein JT, Martens-Lobenhoffer J et al. Erythropoietin increases asymmetric dimethylarginine in endothelial cells: role of dimethylarginine dimethylaminohydrolase. J Am Soc Nephrol 2005; 16: 892-898.
19. Wang XQ, Vaziri ND. Erythropoietin depresses nitric oxide synthase expression by human endothelial cells. Hypertension 1999; 33: 894-899.
20. Singh AK. The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis. Clin J Am Soc Nephrol 2010; 5: 553-556.
21. Szczech LA, Barnhart HX, Inrig JK et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008; 74: 791-798.
22. Unger EF, Thompson AM, Blank MJ et al. Erythropoiesis-stimulating agents-time for a reevaluation. N Engl J Med 2010; 362: 189-192.
23. Zhang Y, Thamer M, Stefanik K et al. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 2004; 44: 866-876.
24. Pan W. Akaike's information criterion in generalized estimating equations. Biometrics 2001; 57: 120-125.
25. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590.
26. Conlon PJ, Kovalik E, Schumm D et al. Normalization of hematocrit in hemodialysis patients with cardiac disease does not increase blood pressure. Ren Fail 2000; 22: 435-444.
27. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084.
28. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. The US Recombinant Human Erythropoietin Predialysis Study Group. Am J Kidney Dis 1991; 18: 50-59.
29. Pollok M, Bommer J, Gurland HJ et al. Effects of recombinant human erythropoietin treatment in end-stage renal failure patients. Results of a multicenter phase II/III study. Contrib Nephrol 1989; 76: 201-211. discussion 12-18.
30. Effect of recombinant human erythropoietin therapy on blood pressure in hemodialysis patients. Canadian Erythropoietin Study Group. Am J Nephrol 1991; 11: 23-26.
31. Narayan P, Papademetriou V, Wachtell K et al. Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan intervention for End Point Reduction in Hypertension Study. Hypertension 2006; 47: 868-873.
32. Kengne AP, Czernichow S, Huxley R et al. Blood pressure variables and cardiovascular risk: new findings from ADVANCE. Hypertension 2009; 54: 399-404.
33. Klassen PS, Lowrie EG, Reddan DN et al. Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA 2002; 287: 1548-1555.
34. Panagiotakos DB, Kromhout D, Menotti A et al. The relation between pulse pressure and cardiovascular mortality in 12,763 middle-aged men from various parts of the world: a 25-year followup of the seven countries study. Arch Intern Med 2005; 165: 2142-2147.